Binnopharm Group has been ranked second among of the best pharmaceutical manufacturers in Russia according to Forbes

Binnopharm Group has been recognised as one of the industry leaders, ranking second in Forbes’ 2024 ranking of Russia’s best pharmaceutical companies.

Binnopharm Group’s key achievements in the rating include a diversified product portfolio that allows it to offer a wide range of drugs to the market, active export development, the launch of its own product portfolio on foreign markets and growing economic performance.

Last year, Binnopharm Group produced more than 350 million packages of drugs. In total, the company’s portfolio includes more than 480 marketing authorisations (MA). From 2022 to 2024, Binnopharm Group conducted 42 clinical trials.

In 2024, the company demonstrated high growth rates in retail sales — an increase of 19% compared to 2023, reaching an amount of more than 48 billion rubles. The pharmaceuticals produced by Binnopharm Group are available in 15 countries around the world. The company continues to actively expand its international presence, with representative offices already opened in Vietnam and China. The company has applied for registration of its flagship product Neobutin in PRC.

The Forbes ranking is based on an analysis of the 40 largest Russian manufacturers by sales volume in 2024, according to AlphaRM. Only finished dosage forms (FDF) of drugs produced in Russia were included in the calculation. Companies were ranked according to four criteria: sales in 2024, change in sales for the year, number of the company’s drug brands in circulation in 2024 according to AlphaRM, and number of clinical trial approvals in the last three years.